(3R,4R)-3-(BOC-AMINO)-4-METHYLPIPERIDINE, 95.0%, 250mg

[(1S)-1-(3-isobutyl-1,2,4-oxadiazol-5-yl)ethyl]amine hydrochloride, 95.0%, 250mg

5-metoxiindol, mínimo 98 %, para síntesis, 1 g, envase de vidrio

(S)-N-(4-(2,5-Dioxooxazolidin-4-yl)butyl)-2,2,2-trifluoroacetamide, 95.0%, 100g

(2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid, 98.0%, 10g

2-(3-Bromophenyl)triphenylene, 97%, 25g

4-(Chloromethyl)-2-thiophenecarbaldehyde, 95.0%, 1g

4-tert-Butylbenzoylacetonitrile, 96.0%, 1g

4-((2,2,10,10-Tetramethyl-4,8-dioxo-3,9-dioxa-5,7-diazaundecan-6-ylidene)amino)butanoic acid, 97%, 100mg

Benzyl 2-hydroxy-7-azaspiro[3.5]nonane-7-carboxylate, 95.0%, 100mg

N,N'-BIS(BOC)-N''-(4-HYDROXYBUTYL)GUANIDINE, 95%, 10g

4-Azidobutanoic acid, 500mg

2-Methyl-4H-thieno[3,2-b]pyrrole-5-carboxylic acid, 95.0%, 5g